High-dose pilot study with the novel progestogen dienogestin patients with endometriosis.
High-dose dienogest (20 mg/day) was used for the treatment of endometriosis in women aged 18-52 years after laparoscopic and histological diagnosis of endometriosis and staging according to the revised American Fertility Society criteria. Treatment efficacy was analyzed objectively by second-look laparoscopy, and serum hormone measurements and evaluation of endometriosis-related symptoms were performed done and side-effects recorded. Compared with other high-dose progestin therapies, treatment with dienogest was shown to be effective even in stage IV endometriosis. The side-effect profile of the high-dose dienogest treatment appears to be highly favorable compared with other treatments. Neither the menopausal symptoms caused by therapy with gonadotropin-releasing hormone agonists nor the adverse androgen-related effects induced by danazol were observed. Therefore, long-term high-dose dienogest therapy can be recommended particularly for women with progressive endometriosis.
Schindler
A E
AE
Department of Gynecology and Obstetrics, University of Essen, Essen, Germany. schindler@uni-essen
Christensen
B
B
Henkel
A
A
Oettel
M
M
Moore
C
C
D000328:Adult; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D006727:Hormone Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D009277:Nandrolone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D010865:Pilot Projects; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
D006727:Hormone Antagonists; C023635:dienogest; D009277:Nandrolone